Alkem Laboratories Results Earnings Call for Q1FY24
Conference Call with Alkem Laboratories Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.10-08-2023
10-08-2023
Q1FY24 Quarterly Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals company Alkem Laboratories announced Q1FY24 results: Total revenue from operations was Rs 29,677 million, YoY growth of 15.2% India sales were Rs 19,007 million, YoY growth of 6.7% International sales were Rs 10,146 million, YoY growth of 33.4% Earnings before interest, tax, depreciation, and amortization (EBITDA) was Rs 3,892 million, resulting in an EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY. R&D; expenses for Q1FY24 were Rs 1,202 million, or 4.1% of total revenue from operations compared to Rs 1,320 million in Q1FY23 at 5.1% of total revenue from operations. Profit before tax (PBT) was Rs 3,529 million, a growth of 132.3% compared to Q1FY23. Net profit (after Minority Interest) was Rs 2,867 million, YoY growth of 124.6%. Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "We are starting the year on a healthy note, showcasing better operational performance driven by improved margins resulting from softening of select raw material prices, favourable currency impact, easing of freight cost and implementation of some of our cost optimization efforts. Our acute business growth was impacted by the delayed onset of monsoon in certain parts of the country, yet we maintain an optimistic outlook for improved growth in Q2. International business achieved robust sales during the quarter, driven by substantial growth in our US operations and complemented by strong performance in non-US markets. Our biosimilar franchise, Enzene is steadily expanding its product portfolio in India, with two successful launches this quarter, bringing the total count of products to six—an impressive achievement for the company. Our cost optimization initiatives have started yielding tangible results and we remain committed to further unlocking operational efficiencies going forward.” Result PDF10-08-2023
Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Cut-Off Date For Postal Ballot
This is to inform you that pursuant to the provisions of Sec 110 and other applicable provisions of the Companies Act 2013 read with Rule 20 as and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors of the Company at its meeting held today 10th Aug 23 have decided to seek approval of shareholders by way of Postal Ballot (voting through electronic means) for appointment of Mr.Aniruddha Singh , son of Mrs. Madhurima Singh, Executive Director of the Company to hold office of profit as AVP- CMD office of the Company w.e.f 23rd Nov, 23. The Company has fixed 1st Sept, 23 as the cut off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means.10-08-2023
Alkem Laboratories Ltd - 539523 - Closure of Trading Window
We refer to our earlier communication dated 28th June 23 regarding closure of trading window (for the purpose of Financial Results for the quarter ended 30th June 23) starting from 29th June 23 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 23 are communicated to the Stock exchanges. The financial results of the Company for the quarter ended 30th June 22 have been communicated to the stock exchanges today 10th Aug 23 and the trading window shall open on 14th Aug, 23.10-08-2023
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to relevant provisions of SEBI LODR Reg, 2015 we enclose herewith press release and analyst presentation on Q1FY24 earnings and business updates and the same shall be uploaded on the website of the Company.10-08-2023
Alkem Laboratories Ltd - 539523 - Results- Financial Results For Quarter Ended June 30, 2023
Kindly refer to our intimation letter dated 31st July 23 pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (LODR) Reg, 2015. We are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June 23 duly approved by the BOD of the Company at its meeting held today i.e 10th Aug, 23. A copy of the Unaudited Financial Results and Limited Review Report is enclosed herewith. The meeting of BOD commenced at 11.45 and concluded at 1.45 pm.10-08-2023
Alkem Laboratories Ltd - 539523 - Board Meeting Outcome for Outcome Of The Board Meeting Dated 10Th Aug 23
The Board of Directors of the Company, at its meeting held today, i.e. 10.08.2023 have approved the Standalone and Consolidated Unaudited Financial Results for the QE 30.06 2023. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Reg 33 of the Listing Regulations, is enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.45 A.M and concluded at 1.45 P.M. Kindly take the same on record.10-08-2023
Dividend Stocks: Alkem Laboratories, Goa Carbon among 17 stocks to trade ex-dividend today - August 10
A total of seventeen stocks will trade ex-dividend today. The ex-dividend date is the day on which the price of an equity share adjusts to reflect the next dividend payout.10-08-2023
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q1FY24 financial results will be held on Thursday, 10th August, 2023 at 04.00 p.m. Please find attached herewith the conference call details. Kindly take note of the same.31-07-2023
Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2023. Kindly take note of the same.31-07-2023